Guidelines for stroke prevention in patients with atrial fibrillation

Drugs

Volumn 58, Issue 6, 1999, Pages 997-1009

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

AGE; BLEEDING; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT EDUCATION; POLYPHARMACY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; REVIEW; RISK; RISK FACTOR; SECONDARY PREVENTION; SINUS RHYTHM; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0033392518     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958060-00004     Document Type: Review

References (51)

1. 1. Feinberg WM, Blackshear JL, Laupacia A. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469-73
2. 2. Hart RG, Sherman DG, Easton D, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51: 674-81
3. 3. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas [editorial]. Stroke 1988; 19: 937-41
4. 4. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S-89S
5. 5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-8
6. 6. Gresham GE, Duncan PW, Stason WP, et al. Post-stroke rehabilitation. Clinical Practice Guideline, No. 16. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 95-0662, May 1995
7. 7. Atrial Fibrillation Follow-up Investigation of Rhythm Management - The AFFIRM Study Design. Am J Cardiol 1997; 79: 1198-201
8. 8. Boston Area Anticoagulation Trial for Atrial Fibrillation Invesligators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11
9. 9. Petersen P, Godfredsen J, Boysen G, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagan AFASAK Study. Lancet 1989; 1: 175-9
10. 10. Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-39
11. 11. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55
12. 12. Ezekowitz MD, Bridgers SL, James KE, et al. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12
13. 13. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-91
14. 14. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996; 348: 633-8
15. 15. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibirllation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513-21
16. 16. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57
17. 17. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Arch Intern Med 1997; 157: 1237-40
18. 18. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology 1993; 43: 32-6
19. 19. Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Neurology 1996; 46; 238-40
20. 20. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62
21. 21. Morocutti C, Giuseppe A, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28: 1015-21
22. 22. Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13
23. 23. Benavente, O, Hart RG. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997; 153: 110-2
24. 24. Connolly S, for the Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation II study [letter]. Lancet 1994; 343: 1509
25. 25. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-16
26. 26. Finn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993; 118: 511-20
27. 27. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7
28. 28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902
29. 29. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
30. 30. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6
31. 31. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-81
32. 32. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154: 1443-8
33. 33. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279: 1273-7
34. 34. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5
35. 35. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994; 121: 54-5
36. 36. Stroke prevention recommendations. Rockville MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 95-0091, September 1995
37. 37. ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. Am J Health Syst Pharm 1998; 55: 376-81
38. 38. Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-60
39. 39. Gage BF, Cardinali AB, Albers G, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with atrial fibrillation. JAMA 1995; 274: 1839-45
40. 40. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in primary prevention of ischemic stroke. Stroke 1998; 29: 1827-32
41. 41. Matchar DB, Samsa GP. Secondary and tertiary prevention of stroke: patient outcomes research team: excerpts, seventh progress report. Durham NC: Center for Health Policy Research and Education. Duke University, 1995
42. 42. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-53
43. 43. Leitner DA, McCart GM, Knoell K. Evaluation of anticoagulation for chronic skilled-nursing facility residents. Consult Pharm 1994; 9: 880-914
44. 44. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 2311-6
45. 45. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996; 156: 2537-41
46. 46. Llop R, Ferrer A, Agusti A, et al. From clinical trials to clinical practice: oral anticoagulation among patients with non-rheumatic atrial fibrillation. Eur J Clin Pharmacol 1997; 53: 1-5
47. 47. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-3
48. 48. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5mg and 10mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133-6
49. 49. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10: 381-94
50. 50. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83
51. 51. Harris JE. Interaction of dietary factors with oral anticoagulants: review and application. J Am Diet Assoc 1995; 95: 580-4